Illumina (ILMN) Optics for Genomics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Illumina (ILMN) Optics for Genomics

ILMN 120.74

-1.4%

3:34 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mopgcw who wrote (37)	10/4/2002 12:11:36 AM
From: mopgcw	Read Replies (1) of 276

Illumina Appoints Susan Eddins to Head Worldwide Marketing Businesswire, Tuesday, October 01, 2002 at 17:34 SAN DIEGO, Oct 1, 2002 (BUSINESS WIRE) -- Illumina, Inc. (Nasdaq: ILMN) announced today the appointment of Susan Eddins as Head of Worldwide Marketing. In this new position, Ms. Eddins will be responsible for marketing and product management of the company's high-throughput BeadArray(TM) and Oligator(TM) technology platforms, products and services. Ms. Eddins was previously Director of Genomic Assays at Applied Biosystems, where she was responsible for the commercialization strategies for genotyping and gene expression assays as well as custom oligonucleotide synthesis. She joined Applied Biosystems in 1994 as a Product Specialist in the electrophoresis marketing group. Ms. Eddins was responsible for the product management and strategic marketing of the ABI PRISM 3700 DNA Analyzer. The capillary electrophoresis system was used by both the public and private efforts involved in the Human Genome Sequencing project. Before joining Applied Biosystems Ms. Eddins was involved in product management and strategic planning in the electronic design automation (EDA) industry. Jay Flatley, Illumina President and CEO, commented,"Susan brings a vast wealth of experience in the markets and technologies directly related to Illumina's business. We welcome Susan to our management team and we look forward to her contributions in building the marketing strategy of our business."Illumina (Nasdaq: ILMN; www.illumina.com) is developing next-generation tools that permit large-scale analysis of genetic variation and function. The Company's proprietary BeadArray(TM) technology can provide the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will help pave the way to personalized medicine.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next